Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis.

EAE Ppargc1a immunology inflammation mitochondria mouse multiple sclerosis neuroprotection neuroscience oxidative phosphorylation

Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
10 02 2021
Historique:
received: 05 08 2020
accepted: 10 02 2021
pubmed: 11 2 2021
medline: 2 2 2022
entrez: 10 2 2021
Statut: epublish

Résumé

While transcripts of neuronal mitochondrial genes are strongly suppressed in central nervous system inflammation, it is unknown whether this results in mitochondrial dysfunction and whether an increase of mitochondrial function can rescue neurodegeneration. Here, we show that predominantly genes of the electron transport chain are suppressed in inflamed mouse neurons, resulting in impaired mitochondrial complex IV activity. This was associated with post-translational inactivation of the transcriptional co-regulator proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). In mice, neuronal overexpression of Multiple sclerosis is a life-long neurological condition that typically begins when people are in their twenties or thirties. Symptoms vary between individuals, and within a single individual over time, but can include difficulties with vision, balance, movement and thinking. These occur because the immune system of people with multiple sclerosis attacks the brain and spinal cord. This immune assault damages neurons and can eventually cause them to die. But exactly how this happens is unclear, and there are no drugs available that can prevent it. One idea is that the immune attack in multiple sclerosis damages neurons by disrupting structures inside them called mitochondria. These cellular ‘organs’, or organelles, produce the energy that all cells need to function correctly. If the mitochondria fail to generate enough energy, the cells can die. And because neurons are very active cells with high energy demands, they are particularly vulnerable to the effects of mitochondrial damage. By studying a mouse version of multiple sclerosis, Rosenkranz et al. now show that mitochondria in the neurons of affected animals are less active than those of healthy control mice. This is because the genes inside mitochondria that enable the organelles to produce energy are less active in the multiple sclerosis mice. Most of these genes that determine mitochondrial activity and energy production are under the control of a single master gene called PGC-1alpha. Rosenkranz et al. showed that boosting the activity of this gene — by introducing extra copies of it into neurons — increases mitochondrial activity in mice. It also makes the animals more resistant to the effects of multiple sclerosis. Boosting the activity of mitochondria in neurons could thus be a worthwhile therapeutic strategy to investigate for multiple sclerosis. Future studies should examine whether drugs that activate PGC-1alpha, for example, could help prevent neuronal death and the resulting symptoms of multiple sclerosis.

Autres résumés

Type: plain-language-summary (eng)
Multiple sclerosis is a life-long neurological condition that typically begins when people are in their twenties or thirties. Symptoms vary between individuals, and within a single individual over time, but can include difficulties with vision, balance, movement and thinking. These occur because the immune system of people with multiple sclerosis attacks the brain and spinal cord. This immune assault damages neurons and can eventually cause them to die. But exactly how this happens is unclear, and there are no drugs available that can prevent it. One idea is that the immune attack in multiple sclerosis damages neurons by disrupting structures inside them called mitochondria. These cellular ‘organs’, or organelles, produce the energy that all cells need to function correctly. If the mitochondria fail to generate enough energy, the cells can die. And because neurons are very active cells with high energy demands, they are particularly vulnerable to the effects of mitochondrial damage. By studying a mouse version of multiple sclerosis, Rosenkranz et al. now show that mitochondria in the neurons of affected animals are less active than those of healthy control mice. This is because the genes inside mitochondria that enable the organelles to produce energy are less active in the multiple sclerosis mice. Most of these genes that determine mitochondrial activity and energy production are under the control of a single master gene called PGC-1alpha. Rosenkranz et al. showed that boosting the activity of this gene — by introducing extra copies of it into neurons — increases mitochondrial activity in mice. It also makes the animals more resistant to the effects of multiple sclerosis. Boosting the activity of mitochondria in neurons could thus be a worthwhile therapeutic strategy to investigate for multiple sclerosis. Future studies should examine whether drugs that activate PGC-1alpha, for example, could help prevent neuronal death and the resulting symptoms of multiple sclerosis.

Identifiants

pubmed: 33565962
doi: 10.7554/eLife.61798
pii: 61798
pmc: PMC7993994
doi:
pii:

Banques de données

GEO
['GSE104899']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021, Rosenkranz et al.

Déclaration de conflit d'intérêts

SR, AS, ST, JE, MW, VR, VV, NP, SB, CS, CS, LB, BS, OP, Jv, MF, MF No competing interests declared

Références

Neuron. 2019 Feb 20;101(4):615-624.e5
pubmed: 30686733
Cell Metab. 2005 Jun;1(6):361-70
pubmed: 16054085
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Acta Neuropathol. 2013 Feb;125(2):231-43
pubmed: 23073717
Sci Rep. 2017 Feb 17;7:42938
pubmed: 28211497
Cell Calcium. 2020 May;87:102190
pubmed: 32199208
Am J Physiol Cell Physiol. 2007 Feb;292(2):C641-57
pubmed: 17092996
EMBO J. 2017 Jun 1;36(11):1474-1492
pubmed: 28438892
Nat Rev Neurol. 2014 Apr;10(4):225-38
pubmed: 24638138
J Neuroimmunol. 2014 Sep 15;274(1-2):14-9
pubmed: 24999244
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8844-E8853
pubmed: 30185553
Nature. 2007 Jun 21;447(7147):1012-6
pubmed: 17554339
Nat Rev Neurol. 2014 Aug;10(8):459-68
pubmed: 25002107
Cell Mol Life Sci. 2012 Apr;69(7):1153-65
pubmed: 21984601
Lancet. 2018 Mar 31;391(10127):1263-1273
pubmed: 29576505
Nat Neurosci. 2019 Jun;22(6):887-896
pubmed: 31011226
J Immunol. 2013 May 1;190(9):4595-607
pubmed: 23547115
Cell. 2008 Nov 14;135(4):738-48
pubmed: 19013281
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Sci Transl Med. 2010 Oct 6;2(52):52ra73
pubmed: 20926834
Nature. 2012 Nov 15;491(7424):374-83
pubmed: 23151580
Aging Cell. 2007 Jun;6(3):337-50
pubmed: 17328689
Brain. 2009 May;132(Pt 5):1161-74
pubmed: 19293237
Hum Mol Genet. 2014 May 1;23(9):2400-15
pubmed: 24334768
Cell. 1999 Mar 19;96(6):857-68
pubmed: 10102273
Elife. 2017 Nov 27;6:
pubmed: 29173281
Hum Mol Genet. 2012 Dec 1;21(23):5091-105
pubmed: 22922230
J Neurosci. 2014 Oct 22;34(43):14375-87
pubmed: 25339750
Nat Med. 2007 Dec;13(12):1483-9
pubmed: 17994101
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Am J Clin Nutr. 2011 Apr;93(4):884S-90
pubmed: 21289221
Nat Rev Mol Cell Biol. 2018 Nov;19(11):713-730
pubmed: 30143745
Cell. 1998 Mar 20;92(6):829-39
pubmed: 9529258
J Biol Chem. 2010 Jan 22;285(4):2474-87
pubmed: 19940161
Leukemia. 2006 May;20(5):900-4
pubmed: 16511511
Sci STKE. 2004 Feb 03;2004(219):pl5
pubmed: 14872098
Sci Rep. 2016 Sep 14;6:33249
pubmed: 27624721
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Nat Rev Mol Cell Biol. 2012 Sep;13(9):566-78
pubmed: 22850819
Anal Biochem. 2018 Jul 1;552:50-59
pubmed: 28711444
Cell. 2004 Oct 1;119(1):121-35
pubmed: 15454086
Ann Neurol. 2008 Sep;64(3):247-54
pubmed: 18570297
Nat Med. 2012 Dec;18(12):1805-11
pubmed: 23160238
Mitochondrion. 2013 Sep;13(5):417-26
pubmed: 23261681
J Neurosci. 2013 Mar 13;33(11):4657-71
pubmed: 23486940
Cell. 2016 Jun 30;166(1):63-76
pubmed: 27293185
Proc Natl Acad Sci U S A. 2004 May 25;101(21):8168-73
pubmed: 15148385
Ann Neurol. 2008 Sep;64(3):255-65
pubmed: 18661561
Neurobiol Dis. 2009 Oct;36(1):51-9
pubmed: 19591937
J Immunol. 2001 Jul 1;167(1):173-80
pubmed: 11418646
J Neurosci Methods. 2015 Jul 15;249:8-15
pubmed: 25864804
Ann Neurol. 2011 Mar;69(3):481-92
pubmed: 21446022
Nat Immunol. 2008 Oct;9(10):1091-4
pubmed: 18800157
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7558-63
pubmed: 17463082
Nat Rev Drug Discov. 2018 Dec;17(12):865-886
pubmed: 30393373
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6116-6121
pubmed: 28533365
Nat Genet. 2012 Jun 24;44(8):934-40
pubmed: 22729224
Cell. 2012 Sep 28;151(1):96-110
pubmed: 23021218
Lancet Neurol. 2020 Mar;19(3):214-225
pubmed: 31981516
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Lancet Neurol. 2015 Feb;14(2):194-207
pubmed: 25772898
Dev Neurobiol. 2007 Sep 1;67(10):1348-61
pubmed: 17638387
Nat Neurosci. 2016 Dec;19(12):1569-1582
pubmed: 27694991
Nat Med. 2011 Apr;17(4):495-9
pubmed: 21441916
Lancet Neurol. 2017 Oct;16(10):848-856
pubmed: 28920890
FASEB J. 2019 Dec;33(12):14811-14824
pubmed: 31718280
Mult Scler. 2010 Apr;16(4):406-11
pubmed: 20215480

Auteurs

Sina C Rosenkranz (SC)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Artem A Shaposhnykov (AA)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Simone Träger (S)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jan Broder Engler (JB)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Maarten E Witte (ME)

Department of Pathology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.

Vanessa Roth (V)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Vanessa Vieira (V)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Nanne Paauw (N)

Department of Molecular Cell Biology and Immunology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.

Simone Bauer (S)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Celina Schwencke-Westphal (C)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Charlotte Schubert (C)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Lukas Can Bal (LC)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Benjamin Schattling (B)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ole Pless (O)

Fraunhofer ITMP ScreeningPort, Hamburg, Germany.

Jack van Horssen (J)

Department of Molecular Cell Biology and Immunology, Amsterdam UMC, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands.

Marc Freichel (M)

Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.

Manuel A Friese (MA)

Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH